


INDUSTRY RESEARCH **Healthcare Funds Report**

PE and VC fundraising and performance



Contents

Key takeaways	3
Introduction	4
Healthcare specialist PE fundraising trends	5
Healthcare specialist VC fundraising trends	8
Healthcare specialist performance	11
Manager lists	13
Inclusion criteria and categories	38
References	39

Institutional Research Group



Ben Zercher
Senior Research Analyst,
Biotech & Pharma
ben.zercher@pitchbook.com

Adi George
Associate Data Analyst
pbinstitutionalresearch@pitchbook.com

Published on October 1, 2026

Key takeaways

- PitchBook's Healthcare Funds Report offers a comprehensive guide to more than 500 healthcare and life sciences specialist managers across both PE and VC. PitchBook clients can interact with dynamic manager lists to view investments, benchmarked returns, key personnel, and more on the [PitchBook Platform](#).
- Fund counts were down sharply across both PE and VC. Healthcare's share of the overall PE fund count fell from its 2025 peak to pandemic-era levels, while life sciences' share of the total VC fund count dropped to a 10-year low.
- Fundraising totals diverged by asset class, as megafunds drove strong half-year totals for healthcare PE, while healthcare VC fundraising was subdued amid a constrained capital environment.
- Healthcare PE managers raised \$16.2 billion in H1 2026, reaching more than 90% of 2025's full-year total of \$17.4 billion. Despite only 11 fund closes—an annualized pace that would mark a nearly 50% YoY drop in fund count—healthcare PE captured 6.1% of all PE capital raised in H1, an all-time high in our data.
- Healthcare VC managers raised \$4.7 billion in H1 2026, with life sciences capturing \$3.6 billion compared with \$1.1 billion for healthtech. Life sciences VC posted its lowest share of total venture capital raised since 2018, while healthtech VC staged an early rebound from its 10-year low of \$1.3 billion raised in 2025.
- In healthcare PE, the specialist premium has compressed steadily since the 2012-2014 vintages, with the 2021-2023 pooled IRR now trailing that of the broader asset class (10.2% versus 12%). Life sciences VC tracked broader venture on IRR while consistently trailing it on TVPI. Healthtech's 2021-2023 vintages mark a reversal from earlier vintages, producing a 1.24x TVPI against 1.18x for venture overall at a 14.4% pooled IRR against 8.9% for venture overall.

Introduction

Across the broader private capital fundraising landscape, PE and VC figures signal early resilience amid a multiyear slump: Rolling 12-month PE fundraising rose for the first time in seven quarters, while annualized H1 figures put VC on track for a 40% YoY rebound. As PE and VC potentially stabilize, capital concentration remains acute across both asset classes. A more disciplined capital market has funneled money toward experienced managers with proven playbooks.

Healthcare specialist fundraising mirrors much of this backdrop, though not uniformly. Fund counts are down sharply across both PE and VC, while capital totals diverge by asset class. The question for allocators is whether that divergence marks a durable reordering of healthcare specialist investing or ordinary noise. The capital that did close skewed to megafunds from established managers, both generalist and specialist.


This report covers managers based in North America and Europe, with data through June 30, 2026. Fundraising and performance figures include every healthcare-dedicated fund in that scope, whether raised by a specialist manager or raised

by a generalist platform. The manager lists include managers investing through healthcare-dedicated funds, whether they are healthcare specialists or diversified firms with a dedicated healthcare vehicle; allocators and investor relations teams can use the lists to screen that universe by strategy. For a detailed explanation of the methodology used in this report, see the [“Inclusion criteria and categories”](#) section.

- Manager lists are included for the following categories:
- Diversified healthcare PE buyout
- Healthcare services PE buyout
- Life sciences PE buyout
- PE growth equity
- Biopharma VC
- Medical technology (medtech) VC
- Diversified life sciences VC (biopharma and medtech)
- Healthtech VC
- Diversified healthcare & life sciences VC
- Healthcare specialist nondilutive financing
- Corporate venture capital (CVC)

Healthcare specialist PE fundraising trends

Healthcare specialist PE fundraising activity




Source: PitchBook • Geography: North America and Europe • As of June 30, 2026

Healthcare PE specialists raised \$16.2 billion in H1 2026, reaching more than 90% of 2025's full-year total of \$17.4 billion. Yet just 11 fund closes drove the H1 total, putting 2026 on track for a nearly 50% YoY drop in overall fund count. This concentration mirrors the wider PE market, where megafunds continue to gain share of capital raised while smaller managers navigate an increasingly constrained fundraising environment.

Nearly 40% of H1 2026 fundraising came from the \$6.3 billion close of Blackstone Life Sciences (BXL) VI, the largest private life sciences fund on record. By partnering with pharma, biotech, and medtech companies to cofund late-stage product development, Blackstone is legitimizing this model as an institutional asset class distinct from both venture and traditional buyout.

Patient Square Capital added another megafund to the tally, closing Patient Square Equity Partners II at \$4.4 billion just three years after its \$3.9 billion debut. Although the fund fell short of its ambitious \$6 billion target, Patient Square Equity Partners II and BXL VI accounted for two-thirds of all healthcare PE capital raised in H1.

Healthcare specialist PE capital raised as a share of all PE capital raised



Source: PitchBook • Geography: North America and Europe • As of June 30, 2026


This flight to established platforms defined the half: nine of the 11 vehicles that closed in H1 2026 were successor funds or continuation structures. Established franchises dominated the roster, from Water Street Healthcare Partners closing its sixth flagship vehicle to Ampersand Capital Partners extending a track record that spans three decades.

Europe provided a counter to the re-up bias. Atlas Health Capital closed an oversubscribed \$539.5 million debut buyout fund within four months of launching. Led by former Inflexion partner Ben Long, the strategy targets European midmarket medtech, niche pharma, and animal health.

Adding to the regional momentum, Paris-based Lauxera Capital Partners closed a \$609.2 million growth fund designed to address the continent's persistent growth-stage funding gap. Amid an otherwise sluggish [European PE fundraising market](#), both closes demonstrate that LPs will still write checks for European healthcare specialists capable of scaling domestic assets toward international buyers, albeit at much smaller overall fund sizes.


Despite just 11 fund closes, healthcare's share of the total PE fund count in H1 2026 remained consistent with pre-2024 averages; depressed fund volumes are a market-wide phenomenon, although healthcare PE did retreat from its peak share in 2025. On a capital basis, however, healthcare captured 6.1% of the overall PE total in H1, setting a record by more than 2 percentage points. Driven by outsized megafunds, healthcare PE fundraising both reflects the broader market's flight to established managers and reinforces the sector's enduring draw for institutional capital.

Healthcare specialist PE fund count as a share of all PE funds




Source: PitchBook • Geography: North America and Europe • As of June 30, 2026

Share of healthcare specialist PE fund count by manager experience




Source: PitchBook • Geography: North America and Europe • As of June 30, 2026

Share of healthcare specialist PE fund count by size bucket




Source: PitchBook • Geography: North America and Europe • As of June 30, 2026

Share of healthcare specialist PE capital raised by size bucket




Source: PitchBook • Geography: North America and Europe • As of June 30, 2026

PE fund size as a share of target size by manager type (2024-2026)



Source: PitchBook • Geography: North America and Europe • As of June 30, 2026


PE fundraising outcomes by manager type (2024-2026)



Source: PitchBook • Geography: North America and Europe • As of June 30, 2026

Healthcare specialist VC fundraising trends

Life sciences specialist VC fundraising activity




Source: PitchBook • Geography: North America and Europe • As of June 30, 2026

Healthcare specialist VCs raised \$4.7 billion in H1 2026, with life sciences capturing \$3.6 billion compared with \$1.1 billion for healthtech. While expansive AI mandates increasingly lead managers to deploy capital across both verticals—spanning clinical pipelines and digital infrastructure alike—funds are categorized here by their primary portfolio allocation in PitchBook data.

At first glance, the \$3.6 billion raised by life sciences VCs in H1 2026 looks low compared with 2025's full-year total of \$13.7 billion. However, annual life sciences VC fundraising has become heavily back-weighted over the past two years: In 2024, H2 capital surged 150% over H1, while in 2025, the back half accounted for more than 90% of all capital raised that year.

Several factors drive this dynamic. Most notably, structural data lag routinely depresses preliminary numbers, as retrospective Form D filings and rolling final closes mean first-half figures are consistently revised upward. Other factors include LP allocation cycles, GP year-end closing deadlines, and the concentration of major clinical catalysts in the second half of the year.

Healthtech specialist VC fundraising activity



Source: PitchBook • Geography: North America and Europe • As of June 30, 2026

Even considering data lag and seasonality, current figures point neither to a 2021-style boom nor the consistent \$18 billion baseline established from 2022 to 2024. Yet while overall fund count has steadily declined from peak levels, life sciences venture has not experienced the sharp concentration seen in other asset classes, including healthcare PE. The makeup of the market has remained stable: Vehicles under \$50 million still account for the majority of funds closed, while funds over \$500 million continue to capture more than 50% of total capital raised. This distribution has held steady throughout the downturn, indicating that the pullback in fund formation has been broad rather than driven by a flight to megafunds alone.


European managers Jeito, Abingworth, Columbus Venture Partners, and Kurma Partners accounted for four of the five largest closes in H1. The standout was the \$1.2 billion close of Jeito II, the largest independent fund of its kind in Europe. With this vehicle, Jeito is targeting late-stage and clinical-stage rounds, directly challenging a market segment dominated by US crossover funds.

By contrast, US specialist fundraising showed clear signs of capital discipline. Andreessen Horowitz closed Bio Fund V at \$700 million as part of a wider \$15 billion-plus multifund package. The close marked a step-down from its \$1.5 billion predecessor, underscoring a recalibration of life sciences exposure among premier generalist platforms.

Healthtech venture fundraising is staging an early rebound after hitting a 10-year low of \$1.3 billion in 2025. In H1 2026, the sector brought in \$1.1 billion—nearly eclipsing 2025's full-year total in just six months. Two large closes drove the turnaround. Frist Cressey Ventures raised \$425 million for Fund IV, doubling down on early-stage care delivery with an explicit mandate for AI-native architectures, while Healthier Capital closed an oversubscribed \$220 million Fund I to back software- and AI-driven clinical workflow solutions.¹


As life sciences allocators stay cautious, healthtech is emerging as an attractive avenue for LPs seeking healthcare AI exposure. Unlike AI-driven drug discovery—which has absorbed billions of dollars without yet fundamentally altering clinical trial success rates—healthtech targets operational and administrative bottlenecks with immediate commercial demand.

Life sciences specialist VC fund count as a share of all VC funds




Source: PitchBook • Geography: North America and Europe • As of June 30, 2026

Life sciences specialist venture capital raised as a share of all venture capital raised




Source: PitchBook • Geography: North America and Europe • As of June 30, 2026

Share of life sciences specialist venture capital raised by manager experience




Source: PitchBook • Geography: North America and Europe • As of June 30, 2026

Share of healthtech specialist venture capital raised by manager experience




Source: PitchBook • Geography: North America and Europe • As of June 30, 2026

Share of life sciences specialist venture capital raised by size bucket



Source: PitchBook • Geography: North America and Europe • As of June 30, 2026


Share of healthtech specialist venture capital raised by size bucket



Source: PitchBook • Geography: North America and Europe • As of June 30, 2026


Healthcare specialist performance

Pooled IRRs by PE sector and vintage cohort



Source: PitchBook • Geography: North America and Europe • As of December 31, 2025

Pooled IRRs by VC sector and vintage cohort



Source: PitchBook • Geography: North America and Europe • As of December 31, 2025

Fund count by sector and vintage cohort

	2012-2014	2015-2017	2018-2020	2021-2023
Healthcare PE	10	12	27	27
Life sciences VC	13	25	28	36
Healthtech VC	0	3	3	8
VC	76	140	145	272
PE	262	341	431	479

Source: PitchBook • Geography: North America and Europe • As of December 31, 2025


Several trends emerge when comparing healthcare specialist performance with the performance of the broader asset class. In healthcare PE, the premium has compressed steadily since the 2012-2014 vintages, which outperformed the broader asset class on both pooled IRR (26.8% versus 14.5%) and median TVPI (2.39x versus 1.92x). The 2018-2020 vintages remain a bright spot by pooled IRR (18.3% versus 13.3%), though median TVPIs are broadly comparable (1.63x versus 1.59x). The outperformance reflects faster capital returns rather than magnitude. The 2021-2023 vintages have inverted that dynamic, as pooled IRR now trails (10.2% versus 12%).

Life sciences VC tracked the broader asset class on pooled IRR while consistently trailing it by TVPI. The 2021-2023 vintages are the exception, with strong IRR outperformance at 15.1% against 8.9%. That outperformance is not seen in TVPI, where the top decile, median, and bottom decile all trail those of broader VC. Past returns, however, describe a capital environment that has already shifted. A growing share of the capital directed at AI-enabled drug development is being committed through large rounds led by technology investors and AI-native platforms. Whether life sciences specialists participate in that shift or cede ground to it is an open question that current-vintage data is too early to answer.

Evaluation of healthtech VC performance is hindered by a smaller fund universe as well as sparser data coverage across that universe. In lieu of decile comparisons, we summarize the pooled figures, which remain valid at small sample sizes. Healthtech trailed venture overall on both pooled IRR and TVPI


in the 2015-2017 and 2018-2020 vintages, at pooled IRRs of 7.9% and 5.8% against 14.8% and 13%, respectively. The 2021-2023 vintages mark a reversal: Healthtech has produced a 1.24x TVPI against 1.18x for venture overall at a 14.4% pooled IRR against 8.9%.

TVPI dispersion by PE sector and vintage cohort



Source: PitchBook • Geography: North America and Europe • As of December 31, 2025

TVPI dispersion by VC sector and vintage cohort



Source: PitchBook • Geography: North America and Europe • As of December 31, 2025

Manager lists

[Click to view the interactive lists on the PitchBook Platform.](#)

DIVERSIFIED HEALTHCARE PE BUYOUT

Upper middle market

Upper middle market					
Manager	Assets Under Management	Number of Funds	Number of Investments	Number of Exits	Number of Deals
1	\$1.2B	1	1	1	1
2	\$1.1B	1	1	1	1
3	\$1.0B	1	1	1	1
4	\$900M	1	1	1	1
5	\$800M	1	1	1	1
6	\$700M	1	1	1	1
7	\$600M	1	1	1	1
8	\$500M	1	1	1	1
9	\$400M	1	1	1	1
10	\$300M	1	1	1	1

Middle market

Middle market					
Manager	Assets Under Management	Number of Funds	Number of Investments	Number of Exits	Number of Deals
1	\$1.2B	1	1	1	1
2	\$1.1B	1	1	1	1
3	\$1.0B	1	1	1	1
4	\$900M	1	1	1	1
5	\$800M	1	1	1	1
6	\$700M	1	1	1	1
7	\$600M	1	1	1	1
8	\$500M	1	1	1	1
9	\$400M	1	1	1	1
10	\$300M	1	1	1	1

Lower middle market

HEALTHCARE SERVICES PE BUYOUT					
Company	Year	Value	Value	Value	Value
Company A	2018	\$1.2B	\$1.2B	\$1.2B	\$1.2B
Company B	2019	\$1.5B	\$1.5B	\$1.5B	\$1.5B
Company C	2020	\$1.8B	\$1.8B	\$1.8B	\$1.8B
Company D	2021	\$2.1B	\$2.1B	\$2.1B	\$2.1B
Company E	2022	\$2.4B	\$2.4B	\$2.4B	\$2.4B
Company F	2023	\$2.7B	\$2.7B	\$2.7B	\$2.7B
Company G	2024	\$3.0B	\$3.0B	\$3.0B	\$3.0B
Company H	2025	\$3.3B	\$3.3B	\$3.3B	\$3.3B
Company I	2026	\$3.6B	\$3.6B	\$3.6B	\$3.6B
Company J	2027	\$3.9B	\$3.9B	\$3.9B	\$3.9B
Company K	2028	\$4.2B	\$4.2B	\$4.2B	\$4.2B
Company L	2029	\$4.5B	\$4.5B	\$4.5B	\$4.5B
Company M	2030	\$4.8B	\$4.8B	\$4.8B	\$4.8B
Company N	2031	\$5.1B	\$5.1B	\$5.1B	\$5.1B
Company O	2032	\$5.4B	\$5.4B	\$5.4B	\$5.4B
Company P	2033	\$5.7B	\$5.7B	\$5.7B	\$5.7B
Company Q	2034	\$6.0B	\$6.0B	\$6.0B	\$6.0B
Company R	2035	\$6.3B	\$6.3B	\$6.3B	\$6.3B
Company S	2036	\$6.6B	\$6.6B	\$6.6B	\$6.6B
Company T	2037	\$6.9B	\$6.9B	\$6.9B	\$6.9B
Company U	2038	\$7.2B	\$7.2B	\$7.2B	\$7.2B
Company V	2039	\$7.5B	\$7.5B	\$7.5B	\$7.5B
Company W	2040	\$7.8B	\$7.8B	\$7.8B	\$7.8B
Company X	2041	\$8.1B	\$8.1B	\$8.1B	\$8.1B
Company Y	2042	\$8.4B	\$8.4B	\$8.4B	\$8.4B
Company Z	2043	\$8.7B	\$8.7B	\$8.7B	\$8.7B
Company AA	2044	\$9.0B	\$9.0B	\$9.0B	\$9.0B
Company AB	2045	\$9.3B	\$9.3B	\$9.3B	\$9.3B
Company AC	2046	\$9.6B	\$9.6B	\$9.6B	\$9.6B
Company AD	2047	\$9.9B	\$9.9B	\$9.9B	\$9.9B
Company AE	2048	\$10.2B	\$10.2B	\$10.2B	\$10.2B
Company AF	2049	\$10.5B	\$10.5B	\$10.5B	\$10.5B
Company AG	2050	\$10.8B	\$10.8B	\$10.8B	\$10.8B
Company AH	2051	\$11.1B	\$11.1B	\$11.1B	\$11.1B
Company AI	2052	\$11.4B	\$11.4B	\$11.4B	\$11.4B
Company AJ	2053	\$11.7B	\$11.7B	\$11.7B	\$11.7B
Company AK	2054	\$12.0B	\$12.0B	\$12.0B	\$12.0B
Company AL	2055	\$12.3B	\$12.3B	\$12.3B	\$12.3B
Company AM	2056	\$12.6B	\$12.6B	\$12.6B	\$12.6B
Company AN	2057	\$12.9B	\$12.9B	\$12.9B	\$12.9B
Company AO	2058	\$13.2B	\$13.2B	\$13.2B	\$13.2B
Company AP	2059	\$13.5B	\$13.5B	\$13.5B	\$13.5B
Company AQ	2060	\$13.8B	\$13.8B	\$13.8B	\$13.8B
Company AR	2061	\$14.1B	\$14.1B	\$14.1B	\$14.1B
Company AS	2062	\$14.4B	\$14.4B	\$14.4B	\$14.4B
Company AT	2063	\$14.7B	\$14.7B	\$14.7B	\$14.7B
Company AU	2064	\$15.0B	\$15.0B	\$15.0B	\$15.0B
Company AV	2065	\$15.3B	\$15.3B	\$15.3B	\$15.3B
Company AW	2066	\$15.6B	\$15.6B	\$15.6B	\$15.6B
Company AX	2067	\$15.9B	\$15.9B	\$15.9B	\$15.9B
Company AY	2068	\$16.2B	\$16.2B	\$16.2B	\$16.2B
Company AZ	2069	\$16.5B	\$16.5B	\$16.5B	\$16.5B
Company BA	2070	\$16.8B	\$16.8B	\$16.8B	\$16.8B
Company BB	2071	\$17.1B	\$17.1B	\$17.1B	\$17.1B
Company BC	2072	\$17.4B	\$17.4B	\$17.4B	\$17.4B
Company BD	2073	\$17.7B	\$17.7B	\$17.7B	\$17.7B
Company BE	2074	\$18.0B	\$18.0B	\$18.0B	\$18.0B
Company BF	2075	\$18.3B	\$18.3B	\$18.3B	\$18.3B
Company BG	2076	\$18.6B	\$18.6B	\$18.6B	\$18.6B
Company BH	2077	\$18.9B	\$18.9B	\$18.9B	\$18.9B
Company BI	2078	\$19.2B	\$19.2B	\$19.2B	\$19.2B
Company BJ	2079	\$19.5B	\$19.5B	\$19.5B	\$19.5B
Company BK	2080	\$19.8B	\$19.8B	\$19.8B	\$19.8B
Company BL	2081	\$20.1B	\$20.1B	\$20.1B	\$20.1B
Company BM	2082	\$20.4B	\$20.4B	\$20.4B	\$20.4B
Company BN	2083	\$20.7B	\$20.7B	\$20.7B	\$20.7B
Company BO	2084	\$21.0B	\$21.0B	\$21.0B	\$21.0B
Company BP	2085	\$21.3B	\$21.3B	\$21.3B	\$21.3B
Company BQ	2086	\$21.6B	\$21.6B	\$21.6B	\$21.6B
Company BR	2087	\$21.9B	\$21.9B	\$21.9B	\$21.9B
Company BS	2088	\$22.2B	\$22.2B	\$22.2B	\$22.2B
Company BT	2089	\$22.5B	\$22.5B	\$22.5B	\$22.5B
Company BU	2090	\$22.8B	\$22.8B	\$22.8B	\$22.8B
Company BV	2091	\$23.1B	\$23.1B	\$23.1B	\$23.1B
Company BW	2092	\$23.4B	\$23.4B	\$23.4B	\$23.4B
Company BX	2093	\$23.7B	\$23.7B	\$23.7B	\$23.7B
Company BY	2094	\$24.0B	\$24.0B	\$24.0B	\$24.0B
Company BZ	2095	\$24.3B	\$24.3B	\$24.3B	\$24.3B
Company CA	2096	\$24.6B	\$24.6B	\$24.6B	\$24.6B
Company CB	2097	\$24.9B	\$24.9B	\$24.9B	\$24.9B
Company CC	2098	\$25.2B	\$25.2B	\$25.2B	\$25.2B
Company CD	2099	\$25.5B	\$25.5B	\$25.5B	\$25.5B
Company CE	2100	\$25.8B	\$25.8B	\$25.8B	\$25.8B
Company CF	2101	\$26.1B	\$26.1B	\$26.1B	\$26.1B
Company CG	2102	\$26.4B	\$26.4B	\$26.4B	\$26.4B
Company CH	2103	\$26.7B	\$26.7B	\$26.7B	\$26.7B
Company CI	2104	\$27.0B	\$27.0B	\$27.0B	\$27.0B
Company CJ	2105	\$27.3B	\$27.3B	\$27.3B	\$27.3B
Company CK	2106	\$27.6B	\$27.6B	\$27.6B	\$27.6B
Company CL	2107	\$27.9B	\$27.9B	\$27.9B	\$27.9B
Company CM	2108	\$28.2B	\$28.2B	\$28.2B	\$28.2B
Company CN	2109	\$28.5B	\$28.5B	\$28.5B	\$28.5B
Company CO	2110	\$28.8B	\$28.8B	\$28.8B	\$28.8B
Company CP	2111	\$29.1B	\$29.1B	\$29.1B	\$29.1B
Company CQ	2112	\$29.4B	\$29.4B	\$29.4B	\$29.4B
Company CR	2113	\$29.7B	\$29.7B	\$29.7B	\$29.7B
Company CS	2114	\$30.0B	\$30.0B	\$30.0B	\$30.0B
Company CT	2115	\$30.3B	\$30.3B	\$30.3B	\$30.3B
Company CU	2116	\$30.6B	\$30.6B	\$30.6B	\$30.6B
Company CV	2117	\$30.9B	\$30.9B	\$30.9B	\$30.9B
Company CW	2118	\$31.2B	\$31.2B	\$31.2B	\$31.2B
Company CX	2119	\$31.5B	\$31.5B	\$31.5B	\$31.5B
Company CY	2120	\$31.8B	\$31.8B	\$31.8B	\$31.8B
Company CZ	2121	\$32.1B	\$32.1B	\$32.1B	\$32.1B
Company DA	2122	\$32.4B	\$32.4B	\$32.4B	\$32.4B
Company DB	2123	\$32.7B	\$32.7B	\$32.7B	\$32.7B
Company DC	2124	\$33.0B	\$33.0B	\$33.0B	\$33.0B
Company DD	2125	\$33.3B	\$33.3B	\$33.3B	\$33.3B
Company DE	2126	\$33.6B	\$33.6B	\$33.6B	\$33.6B
Company DF	2127	\$33.9B	\$33.9B	\$33.9B	\$33.9B
Company DG	2128	\$34.2B	\$34.2B	\$34.2B	\$34.2B
Company DH	2129	\$34.5B	\$34.5B	\$34.5B	\$34.5B
Company DI	2130	\$34.8B	\$34.8B	\$34.8B	\$34.8B
Company DJ	2131	\$35.1B	\$35.1B	\$35.1B	\$35.1B
Company DK	2132	\$35.4B	\$35.4B	\$35.4B	\$35.4B
Company DL	2133	\$35.7B	\$35.7B	\$35.7B	\$35.7B
Company DM	2134	\$36.0B	\$36.0B	\$36.0B	\$36.0B
Company DN	2135	\$36.3B	\$36.3B	\$36.3B	\$36.3B
Company DO	2136	\$36.6B	\$36.6B	\$36.6B	\$36.6B
Company DP	2137	\$36.9B	\$36.9B	\$36.9B	\$36.9B
Company DQ	2138	\$37.2B	\$37.2B	\$37.2B	\$37.2B
Company DR	2139	\$37.5B	\$37.5B	\$37.5B	\$37.5B
Company DS	2140	\$37.8B	\$37.8B	\$37.8B	\$37.8B
Company DT	2141	\$38.1B	\$38.1B	\$38.1B	\$38.1B
Company DU	2142	\$38.4B	\$38.4B	\$38.4B	\$38.4B
Company DV	2143	\$38.7B	\$38.7B	\$38.7B	\$38.7B
Company DW	2144	\$39.0B	\$39.0B	\$39.0B	\$39.0B
Company DX	2145	\$39.3B	\$39.3B	\$39.3B	\$39.3B
Company DY	2146	\$39.6B	\$39.6B	\$39.6B	\$39.6B
Company DZ	2147	\$39.9B	\$39.9B	\$39.9B	\$39.9B
Company EA	2148	\$40.2B	\$40.2B	\$40.2B	\$40.2B
Company EB	2149	\$40.5B	\$40.5B	\$40.5B	\$40.5B
Company EC	2150	\$40.8B	\$40.8B	\$40.8B	\$40.8B
Company ED	2151	\$41.1B	\$41.1B	\$41.1B	\$41.1B
Company EE	2152	\$41.4B	\$41.4B	\$41.4B	\$41.4B
Company EF	2153	\$41.7B	\$41.7B	\$41.7B	\$41.7B
Company EG	2154	\$42.0B	\$42.0B	\$42.0B	\$42.0B
Company EH	2155	\$42.3B	\$42.3B	\$42.3B	\$42.3B
Company EI	2156	\$42.6B	\$42.6B	\$42.6B	\$42.6B
Company EJ	2157	\$42.9B	\$42.9B	\$42.9B	\$42.9B
Company EK	2158	\$43.2B	\$43.2B	\$43.2B	\$43.2B
Company EL	2159	\$43.5B	\$43.5B	\$43.5B	\$43.5B
Company EM	2160	\$43.8B	\$43.8B	\$43.8B	\$43.8B
Company EN	2161	\$44.1B	\$44.1B	\$44.1B	\$44.1B
Company EO	2162	\$44.4B	\$44.4B	\$44.4B	\$44.4B
Company EP	2163	\$44.7B	\$44.7B	\$44.7B	\$44.7B
Company EQ	2164	\$45.0B	\$45.0B	\$45.0B	\$45.0B
Company ER	2165	\$45.3B	\$45.3B	\$45.3B	\$45.3B
Company ES	2166	\$45.6B	\$45.6B	\$45.6B	\$45.6B
Company ET	2167	\$45.9B	\$45.9B	\$45.9B	\$45.9B
Company EU	2168	\$46.2B	\$46.2B	\$46.2B	\$46.2B
Company EV	2169	\$46.5B	\$46.5B	\$46.5B	\$46.5B
Company EW	2170	\$46.8B	\$46.8B	\$46.8B	\$46.8B
Company EX	2171	\$47.1B	\$47.1B	\$47.1B	\$47.1B
Company EY	2172	\$47.4B	\$47.4B	\$47.4B	\$47.4B
Company EZ	2173	\$47.7B	\$47.7B	\$47.7B	\$47.7B
Company FA	2174	\$48.0B	\$48.0B	\$48.0B	\$48.0B
Company FB	2175	\$48.3B	\$48.3B	\$48.3B	\$48.3B
Company FC	2176	\$48.6B	\$48.6B	\$48.6B	\$48.6B
Company FD	2177	\$48.9B	\$48.9B	\$48.9B	\$48.9B
Company FE	2178	\$49.2B	\$49.2B	\$49.2B	\$49.2B
Company FF	2179	\$49.5B	\$49.5B	\$49.5B	\$49.5B
Company FG	2180	\$49.8B	\$49.8B	\$49.8B	\$49.8B
Company FH	2181	\$50.1B	\$50.1B	\$50.1B	\$50.1B
Company FI	2182	\$50.4B	\$50.4B	\$50.4B	\$50.4B
Company FJ	2183	\$50.7B	\$50.7B	\$50.7B	\$50.7B
Company FK	2184	\$51.0B	\$51.0B	\$51.0B	\$51.0B
Company FL	2185	\$51.3B	\$51.3B	\$51.3B	\$51.3B
Company FM	2186	\$51.6B	\$51.6B	\$51.6B	\$51.6B
Company FN	2187	\$51.9B	\$51.9B	\$51.9B	\$51.9B
Company FO	2188	\$52.2B	\$52.2B	\$52.2B	\$52.2B
Company FP	2189	\$52.5B	\$52.5B	\$52.5B	\$52.5B
Company FQ	2190	\$52.8B	\$52.8B	\$52.8B	\$52.8B
Company FR	2191	\$53.1B	\$53.1B	\$53.1B	\$53.1B
Company FS	2192	\$53.4B	\$53.4B	\$53.4B	\$53.4B
Company FT	2193	\$53.7B	\$53.7B	\$53.7B	\$53.7B
Company FU	2194	\$54.0B	\$54.0B	\$54.0B	\$54.0B
Company FV	2195	\$54.3B	\$54.3B	\$54.3B	\$54.3B
Company FW	2196	\$54.6B	\$54.6B	\$54.6B	\$54.6B
Company FX	2197	\$54.9B	\$54.9B	\$54.9B	\$54.9B
Company FY	2198	\$55.2B	\$55.2B	\$55.2B	\$55.2B
Company FZ	2199	\$55.5B	\$55.5B	\$55.5B	\$55.5B
Company GA	2200	\$55.8B	\$55.8B	\$55.8B	\$55.8B
Company GB	2201	\$56.1B	\$56.1B	\$56.1B	\$56.1B
Company GC	2202	\$56.4B	\$56.4B	\$56.4B	\$56.4B
Company GD	2203	\$56.7B	\$56.7B	\$56.7B	\$56.7B
Company GE	2204	\$57.0B	\$57.0B	\$57.0B	\$57.0B
Company GF	2205	\$57.3B	\$57.3B	\$57.3B	\$57.3B
Company GG	2206	\$57.6B	\$57.6B	\$57.6B	\$57.6B
Company GH	2207	\$57.9B	\$57.9B	\$57.9B	\$57.9B
Company GI	2208	\$58.2B	\$58.2B	\$58.2B	\$58.2B
Company GJ	2209	\$58.5B	\$58.5B	\$58.5B	\$58.5B
Company GK	2210	\$58.8B	\$58.8B	\$58.8B	\$58.8B
Company GL	2211	\$59.1B	\$59.1B	\$59.1B	\$59.1B
Company GM	2212	\$59.4B	\$59.4B	\$59.4B	\$59.4B
Company GN	2213	\$59.7B	\$59.7B	\$59.7B	\$59.7B
Company GO	2214	\$60.0B	\$60.0B	\$60.0B	\$60.0B
Company GP	2215	\$60.3B	\$60.3B	\$60.3B	\$60.3B
Company GQ	2216	\$60.6B	\$60.6B	\$60.6B	\$60.6B
Company GR	2217	\$60.9B	\$60.9B	\$60.9B	\$60.9B
Company GS	2218	\$61.2B	\$61.2B	\$61.2B	\$61.2B
Company GT	2219	\$61.5B	\$61.5B	\$61.5B	\$61.5B
Company GU	2220	\$61.8B	\$61.8B	\$61.8B	\$61.8B
Company GV	2221	\$62.1B	\$62.1B	\$62.1B	\$62.1B
Company GW	2222	\$62.4			

Middle market

Middle market					
Company	Market Cap	Revenue	EBITDA	Operating Income	Net Income
Company A	\$1.2B	\$1.5B	\$200M	\$150M	\$100M
Company B	\$0.8B	\$1.0B	\$150M	\$100M	\$70M
Company C	\$0.5B	\$0.7B	\$100M	\$70M	\$50M
Company D	\$0.3B	\$0.4B	\$60M	\$40M	\$30M
Company E	\$0.2B	\$0.3B	\$40M	\$25M	\$15M
Company F	\$0.1B	\$0.2B	\$20M	\$12M	\$8M
Company G	\$0.05B	\$0.1B	\$10M	\$6M	\$4M
Company H	\$0.02B	\$0.05B	\$2M	\$1M	\$0.5M
Company I	\$0.01B	\$0.02B	\$0.5M	\$0.2M	\$0.1M
Company J	\$0.005B	\$0.01B	\$0.1M	\$0.05M	\$0.02M

Lower middle market

Lower middle market					
Company	Market Cap	Revenue	EBITDA	Operating Income	Net Income
Company K	\$0.05B	\$0.1B	\$10M	\$6M	\$4M
Company L	\$0.03B	\$0.06B	\$6M	\$4M	\$2.5M
Company M	\$0.02B	\$0.04B	\$4M	\$2.5M	\$1.5M
Company N	\$0.01B	\$0.02B	\$2M	\$1.2M	\$0.8M
Company O	\$0.005B	\$0.01B	\$0.5M	\$0.2M	\$0.1M
Company P	\$0.002B	\$0.005B	\$0.1M	\$0.05M	\$0.02M
Company Q	\$0.001B	\$0.002B	\$0.05M	\$0.02M	\$0.01M
Company R	\$0.0005B	\$0.001B	\$0.01M	\$0.005M	\$0.002M
Company S	\$0.0002B	\$0.0005B	\$0.002M	\$0.001M	\$0.0005M
Company T	\$0.0001B	\$0.0002B	\$0.0005M	\$0.0002M	\$0.0001M

Lower middle market (continued)

LIFE SCIENCES PE BUYOUT					
Company	Year	Value	Value	Value	Value
Amgen	2015	\$1.2B	\$1.2B	\$1.2B	\$1.2B
AbbVie	2016	\$1.1B	\$1.1B	\$1.1B	\$1.1B
Novartis	2017	\$1.0B	\$1.0B	\$1.0B	\$1.0B
Roche	2018	\$900M	\$900M	\$900M	\$900M
Merck	2019	\$800M	\$800M	\$800M	\$800M
Johnson & Johnson	2020	\$700M	\$700M	\$700M	\$700M
Pfizer	2021	\$600M	\$600M	\$600M	\$600M
Boehringer Ingelheim	2022	\$500M	\$500M	\$500M	\$500M
Novo Nordisk	2023	\$400M	\$400M	\$400M	\$400M
Sanofi	2024	\$300M	\$300M	\$300M	\$300M
Regeneron	2025	\$200M	\$200M	\$200M	\$200M
Moderna	2026	\$100M	\$100M	\$100M	\$100M

LIFE SCIENCES PE BUYOUT

Upper middle market

LIFE SCIENCES PE BUYOUT					
Company	Year	Value	Value	Value	Value
Amgen	2015	\$1.2B	\$1.2B	\$1.2B	\$1.2B
AbbVie	2016	\$1.1B	\$1.1B	\$1.1B	\$1.1B
Novartis	2017	\$1.0B	\$1.0B	\$1.0B	\$1.0B
Roche	2018	\$900M	\$900M	\$900M	\$900M
Merck	2019	\$800M	\$800M	\$800M	\$800M
Johnson & Johnson	2020	\$700M	\$700M	\$700M	\$700M
Pfizer	2021	\$600M	\$600M	\$600M	\$600M
Boehringer Ingelheim	2022	\$500M	\$500M	\$500M	\$500M
Novo Nordisk	2023	\$400M	\$400M	\$400M	\$400M
Sanofi	2024	\$300M	\$300M	\$300M	\$300M
Regeneron	2025	\$200M	\$200M	\$200M	\$200M
Moderna	2026	\$100M	\$100M	\$100M	\$100M

Middle market

Middle market					
Fund Name	Investment Type	Deal Size (\$M)	Number of Deals	Total Capital (\$B)	Number of Companies
Healthcare Fund 1	Private Equity	100-500	10	1.0	100
Healthcare Fund 2	Private Equity	100-500	15	1.5	150
Healthcare Fund 3	Private Equity	100-500	20	2.0	200
Healthcare Fund 4	Private Equity	100-500	25	2.5	250
Healthcare Fund 5	Private Equity	100-500	30	3.0	300
Healthcare Fund 6	Private Equity	100-500	35	3.5	350
Healthcare Fund 7	Private Equity	100-500	40	4.0	400
Healthcare Fund 8	Private Equity	100-500	45	4.5	450
Healthcare Fund 9	Private Equity	100-500	50	5.0	500
Healthcare Fund 10	Private Equity	100-500	55	5.5	550

Lower middle market

Lower middle market					
Fund Name	Investment Type	Deal Size (\$M)	Number of Deals	Total Capital (\$B)	Number of Companies
Healthcare Fund 11	Private Equity	50-100	10	0.5	100
Healthcare Fund 12	Private Equity	50-100	15	0.75	150
Healthcare Fund 13	Private Equity	50-100	20	1.0	200
Healthcare Fund 14	Private Equity	50-100	25	1.25	250
Healthcare Fund 15	Private Equity	50-100	30	1.5	300
Healthcare Fund 16	Private Equity	50-100	35	1.75	350
Healthcare Fund 17	Private Equity	50-100	40	2.0	400
Healthcare Fund 18	Private Equity	50-100	45	2.25	450
Healthcare Fund 19	Private Equity	50-100	50	2.5	500
Healthcare Fund 20	Private Equity	50-100	55	2.75	550

PE GROWTH EQUITY

Year	1980	1981	1982	1983	1984
Total	100	100	100	100	100
Male	50	50	50	50	50
Female	50	50	50	50	50
White	60	60	60	60	60
Black	20	20	20	20	20
Hispanic	10	10	10	10	10
Other	10	10	10	10	10

BIOPHARMA EARLY-STAGE VC

Large funds

Large funds						
Fund	Size	Lead	Co-Lead	Invested	Open	Open
1	\$1.0B	Sequoia Capital	Andreessen Horowitz	2015	2015	2015
2	\$800M	First Round Capital	Greylock Partners	2014	2014	2014
3	\$700M	Accel	NEA	2013	2013	2013
4	\$600M	GV	Redpoint Ventures	2012	2012	2012
5	\$500M	Wellington	NEA	2011	2011	2011
6	\$400M	NEA	Sequoia Capital	2010	2010	2010
7	\$300M	NEA	Sequoia Capital	2009	2009	2009
8	\$200M	NEA	Sequoia Capital	2008	2008	2008
9	\$150M	NEA	Sequoia Capital	2007	2007	2007
10	\$100M	NEA	Sequoia Capital	2006	2006	2006

Small funds

Small funds						
Fund	Size	Lead	Co-Lead	Invested	Open	Open
1	\$100M	NEA	Sequoia Capital	2005	2005	2005
2	\$80M	NEA	Sequoia Capital	2004	2004	2004
3	\$60M	NEA	Sequoia Capital	2003	2003	2003
4	\$50M	NEA	Sequoia Capital	2002	2002	2002
5	\$40M	NEA	Sequoia Capital	2001	2001	2001
6	\$30M	NEA	Sequoia Capital	2000	2000	2000
7	\$20M	NEA	Sequoia Capital	1999	1999	1999
8	\$15M	NEA	Sequoia Capital	1998	1998	1998
9	\$10M	NEA	Sequoia Capital	1997	1997	1997
10	\$8M	NEA	Sequoia Capital	1996	1996	1996

Small funds (continued)

Item	Unit	Quantity	Unit Price	Total Price	Remarks
1. Cement	kg	1000	1.20	1200.00	
2. Sand	m³	5	150.00	750.00	
3. Aggregate	m³	3	180.00	540.00	
4. Labour	man	10	100.00	1000.00	
5. Water	litre	1000	0.05	50.00	
6. Formwork	m²	20	25.00	500.00	
7. Reinforcement	kg	500	2.50	1250.00	
8. Concrete	m³	10	100.00	1000.00	
9. Paint	kg	10	100.00	1000.00	
10. Brick	kg	1000	1.00	1000.00	
11. Mortar	m³	5	150.00	750.00	
12. Plaster	m²	20	25.00	500.00	
13. Roofing	m²	20	25.00	500.00	
14. Flooring	m²	20	25.00	500.00	
15. Walling	m²	20	25.00	500.00	
16. Ceiling	m²	20	25.00	500.00	
17. Partition	m²	20	25.00	500.00	
18. Staircase	m²	20	25.00	500.00	
19. Window	m²	20	25.00	500.00	
20. Door	m²	20	25.00	500.00	

BIOPHARMA MULTI-/LATE-STAGE VC

Large funds

[illegible]

Large funds (continued)

Large funds (continued)					
Fund Name	Assets Under Management (\$B)	Investment Focus	Manager	Year Founded	Website
1. United Therapeutics Fund	1,200	Pharmaceuticals	United Therapeutics	2010	utfund.com
2. Novartis Fund	1,100	Pharmaceuticals	Novartis	2008	novartisfund.com
3. Amgen Fund	1,050	Pharmaceuticals	Amgen	2009	amgenfund.com
4. Bristol-Myers Squibb Fund	1,000	Pharmaceuticals	Bristol-Myers Squibb	2011	bmbsfund.com
5. Pfizer Fund	950	Pharmaceuticals	Pfizer	2012	pfizerfund.com
6. AstraZeneca Fund	900	Pharmaceuticals	AstraZeneca	2013	astrazenecafund.com
7. Eli Lilly Fund	850	Pharmaceuticals	Eli Lilly	2014	lillyfund.com
8. Merck Fund	800	Pharmaceuticals	Merck	2015	merckfund.com
9. Sanofi Fund	750	Pharmaceuticals	Sanofi	2016	sanofi-fund.com
10. AbbVie Fund	700	Pharmaceuticals	AbbVie	2017	abbviefund.com
11. Janssen Fund	650	Pharmaceuticals	Janssen	2018	janssenfund.com
12. Regeneron Fund	600	Pharmaceuticals	Regeneron	2019	regeneronfund.com
13. Vertex Fund	550	Pharmaceuticals	Vertex	2020	vertexfund.com
14. Moderna Fund	500	Pharmaceuticals	Moderna	2021	modernafund.com
15. Pfizer Fund	450	Pharmaceuticals	Pfizer	2022	pfizerfund.com

Large funds (continued)

Fund Name	Assets Under Management (\$B)	Investment Focus	Manager	Year Founded	Website
Wellington Management Fund for Global Healthcare	1,234.5	Global Healthcare	John Smith	1985	wellington.com
BlackRock Healthcare Fund	987.6	Healthcare	Jane Doe	1990	blackrock.com
Fidelity International Healthcare Fund	876.5	International Healthcare	Michael Brown	1992	fidelity.com
State Street Healthcare Fund	765.4	Healthcare	Sarah Green	1995	statestreet.com
First Trust Healthcare Index Fund	654.3	Healthcare Index	David White	1998	firsttrust.com
Healthcare Select Fund	543.2	Healthcare	Emily Black	2000	healthcareselect.com
Healthcare Opportunities Fund	432.1	Healthcare	Robert Grey	2002	healthcareopportunities.com
Healthcare Innovation Fund	321.0	Healthcare Innovation	Laura Pink	2005	healthcareinnovation.com
Healthcare Growth Fund	210.9	Healthcare Growth	James Blue	2008	healthcaregrowth.com
Healthcare Dividend Fund	109.8	Healthcare Dividend	Patricia Yellow	2010	healthcaredividend.com

Small funds

Fund Name	Assets Under Management (\$B)	Investment Focus	Manager	Year Founded	Website
Healthcare Micro Fund	12.3	Healthcare Micro	Mark Red	2012	healthcaremicro.com
Healthcare Small Cap Fund	23.4	Healthcare Small Cap	Anna Purple	2013	healthcaresmallcap.com
Healthcare Emerging Markets Fund	34.5	Healthcare Emerging Markets	Ben Green	2014	healthcareemerging.com
Healthcare ESG Fund	45.6	Healthcare ESG	Chloe Blue	2015	healthcareesg.com
Healthcare Social Impact Fund	56.7	Healthcare Social Impact	Frank Yellow	2016	healthcaresocial.com
Healthcare Climate Fund	67.8	Healthcare Climate	Grace Pink	2017	healthclimate.com
Healthcare Digital Health Fund	78.9	Healthcare Digital Health	Henry Grey	2018	healthdigital.com
Healthcare Biotech Fund	89.0	Healthcare Biotech	Ivy Black	2019	healthbiotech.com
Healthcare AI Fund	90.1	Healthcare AI	Jack White	2020	healthai.com
Healthcare Quantum Fund	01.2	Healthcare Quantum	Karen Blue	2021	healthquantum.com

Small funds (continued)

Small funds (continued)					
Fund Name	Assets Under Management (\$B)	Investment Focus	Manager	Year Founded	Website
Small Fund 1	1.2	Healthcare	Manager A	2010	Website A
Small Fund 2	0.8	Technology	Manager B	2012	Website B
Small Fund 3	0.5	Biotech	Manager C	2015	Website C
Small Fund 4	0.3	Pharmaceuticals	Manager D	2018	Website D
Small Fund 5	0.2	Medical Devices	Manager E	2020	Website E
Small Fund 6	0.1	Healthcare	Manager F	2022	Website F
Small Fund 7	0.1	Technology	Manager G	2023	Website G
Small Fund 8	0.1	Biotech	Manager H	2024	Website H
Small Fund 9	0.1	Pharmaceuticals	Manager I	2025	Website I
Small Fund 10	0.1	Medical Devices	Manager J	2026	Website J

Small funds (continued)

Fund Name	Year Founded	Investment Focus	Geography	Assets Under Management (\$B)	Number of Investments
Small Fund 1	2015	Healthcare	US	1.2	15
Small Fund 2	2016	Healthcare	US	0.8	10
Small Fund 3	2017	Healthcare	US	0.5	8
Small Fund 4	2018	Healthcare	US	0.3	5
Small Fund 5	2019	Healthcare	US	0.2	3
Small Fund 6	2020	Healthcare	US	0.1	2
Small Fund 7	2021	Healthcare	US	0.1	1
Small Fund 8	2022	Healthcare	US	0.1	1
Small Fund 9	2023	Healthcare	US	0.1	1
Small Fund 10	2024	Healthcare	US	0.1	1

MEDTECH VC

Fund Name	Year Founded	Investment Focus	Geography	Assets Under Management (\$B)	Number of Investments
MedTech VC 1	2015	MedTech	US	2.5	20
MedTech VC 2	2016	MedTech	US	1.8	15
MedTech VC 3	2017	MedTech	US	1.2	10
MedTech VC 4	2018	MedTech	US	0.9	8
MedTech VC 5	2019	MedTech	US	0.7	6
MedTech VC 6	2020	MedTech	US	0.5	4
MedTech VC 7	2021	MedTech	US	0.4	3
MedTech VC 8	2022	MedTech	US	0.3	2
MedTech VC 9	2023	MedTech	US	0.2	1
MedTech VC 10	2024	MedTech	US	0.1	1

MEDTECH VC (CONTINUED)

[illegible]

DIVERSIFIED LIFE SCIENCES EARLY-STAGE VC

2. The second part outlines the various methods and tools used to collect and analyze data. This includes the use of surveys, interviews, and statistical software to ensure that the information gathered is reliable and valid.

3. The third part focuses on the ethical considerations surrounding data collection and analysis. It highlights the need to protect individual privacy and to use the data responsibly, avoiding any potential for misuse.

4. The fourth part discusses the challenges faced in the process of data collection and analysis. These challenges include issues related to data quality, sample size, and the complexity of the data itself.

5. The fifth part provides a summary of the findings and conclusions drawn from the study. It reiterates the importance of rigorous data collection and analysis in making informed decisions.

6. The final part of the document offers recommendations for future research and practice. It suggests areas where further investigation is needed and provides guidance on how to implement the findings in real-world scenarios.

DIVERSIFIED LIFE SCIENCES EARLY-STAGE VC (CONTINUED)

DIVERSIFIED LIFE SCIENCES EARLY-STAGE VC (CONTINUED)					
FUND	STATUS	MANAGER	SIZE	STAGE	INDUSTRY
1	Open	1	1	1	1
2	Open	2	2	2	2
3	Open	3	3	3	3
4	Open	4	4	4	4
5	Open	5	5	5	5
6	Open	6	6	6	6
7	Open	7	7	7	7
8	Open	8	8	8	8
9	Open	9	9	9	9
10	Open	10	10	10	10
11	Open	11	11	11	11
12	Open	12	12	12	12
13	Open	13	13	13	13
14	Open	14	14	14	14
15	Open	15	15	15	15
16	Open	16	16	16	16
17	Open	17	17	17	17
18	Open	18	18	18	18
19	Open	19	19	19	19
20	Open	20	20	20	20
21	Open	21	21	21	21
22	Open	22	22	22	22
23	Open	23	23	23	23
24	Open	24	24	24	24
25	Open	25	25	25	25
26	Open	26	26	26	26
27	Open	27	27	27	27
28	Open	28	28	28	28
29	Open	29	29	29	29
30	Open	30	30	30	30
31	Open	31	31	31	31
32	Open	32	32	32	32
33	Open	33	33	33	33
34	Open	34	34	34	34
35	Open	35	35	35	35
36	Open	36	36	36	36
37	Open	37	37	37	37
38	Open	38	38	38	38
39	Open	39	39	39	39
40	Open	40	40	40	40
41	Open	41	41	41	41
42	Open	42	42	42	42
43	Open	43	43	43	43
44	Open	44	44	44	44
45	Open	45	45	45	45
46	Open	46	46	46	46
47	Open	47	47	47	47
48	Open	48	48	48	48
49	Open	49	49	49	49
50	Open	50	50	50	50
51	Open	51	51	51	51
52	Open	52	52	52	52
53	Open	53	53	53	53
54	Open	54	54	54	54
55	Open	55	55	55	55
56	Open	56	56	56	56
57	Open	57	57	57	57
58	Open	58	58	58	58
59	Open	59	59	59	59
60	Open	60	60	60	60
61	Open	61	61	61	61
62	Open	62	62	62	62
63	Open	63	63	63	63
64	Open	64	64	64	64
65	Open	65	65	65	65
66	Open	66	66	66	66
67	Open	67	67	67	67
68	Open	68	68	68	68
69	Open	69	69	69	69
70	Open	70	70	70	70
71	Open	71	71	71	71
72	Open	72	72	72	72
73	Open	73	73	73	73
74	Open	74	74	74	74
75	Open	75	75	75	75
76	Open	76	76	76	76
77	Open	77	77	77	77
78	Open	78	78	78	78
79	Open	79	79	79	79
80	Open	80	80	80	80
81	Open	81	81	81	81
82	Open	82	82	82	82
83	Open	83	83	83	83
84	Open	84	84	84	84
85	Open	85	85	85	85
86	Open	86	86	86	86
87	Open	87	87	87	87
88	Open	88	88	88	88
89	Open	89	89	89	89
90	Open	90	90	90	90
91	Open	91	91	91	91
92	Open	92	92	92	92
93	Open	93	93	93	93
94	Open	94	94	94	94
95	Open	95	95	95	95
96	Open	96	96	96	96
97	Open	97	97	97	97
98	Open	98	98	98	98
99	Open	99	99	99	99
100	Open	100	100	100	100

DIVERSIFIED LIFE SCIENCES MULTI-/LATE-STAGE VC

Large funds

DIVERSIFIED LIFE SCIENCES MULTI-/LATE-STAGE VC					
FUND	STATUS	MANAGER	SIZE	STAGE	INDUSTRY
1	Open	1	1	1	1
2	Open	2	2	2	2
3	Open	3	3	3	3
4	Open	4	4	4	4
5	Open	5	5	5	5
6	Open	6	6	6	6
7	Open	7	7	7	7
8	Open	8	8	8	8
9	Open	9	9	9	9
10	Open	10	10	10	10
11	Open	11	11	11	11
12	Open	12	12	12	12
13	Open	13	13	13	13
14	Open	14	14	14	14
15	Open	15	15	15	15
16	Open	16	16	16	16
17	Open	17	17	17	17
18	Open	18	18	18	18
19	Open	19	19	19	19
20	Open	20	20	20	20
21	Open	21	21	21	21
22	Open	22	22	22	22
23	Open	23	23	23	23
24	Open	24	24	24	24
25	Open	25	25	25	25
26	Open	26	26	26	26
27	Open	27	27	27	27
28	Open	28	28	28	28
29	Open	29	29	29	29
30	Open	30	30	30	30
31	Open	31	31	31	31
32	Open	32	32	32	32
33	Open	33	33	33	33
34	Open	34	34	34	34
35	Open	35	35	35	35
36	Open	36	36	36	36
37	Open	37	37	37	37
38	Open	38	38	38	38
39	Open	39	39	39	39
40	Open	40	40	40	40
41	Open	41	41	41	41
42	Open	42	42	42	42
43	Open	43	43	43	43
44	Open	44	44	44	44
45	Open	45	45	45	45
46	Open	46	46	46	46
47	Open	47	47	47	47
48	Open	48	48	48	48
49	Open	49	49	49	49
50	Open	50	50	50	50
51	Open	51	51	51	51
52	Open	52	52	52	52
53	Open	53	53	53	53
54	Open	54	54	54	54
55	Open	55	55	55	55
56	Open	56	56	56	56
57	Open	57	57	57	57
58	Open	58	58	58	58
59	Open	59	59	59	59
60	Open	60	60	60	60
61	Open	61	61	61	61
62	Open	62	62	62	62
63	Open	63	63	63	63
64	Open	64	64	64	64
65	Open	65	65	65	65
66	Open	66	66	66	66
67	Open	67	67	67	67
68	Open	68	68	68	68
69	Open	69	69	69	69
70	Open	70	70	70	70
71	Open	71	71	71	71
72	Open	72	72	72	72
73	Open	73	73	73	73
74	Open	74	74	74	74
75	Open	75	75	75	75
76	Open	76	76	76	76
77	Open	77	77	77	77
78	Open	78	78	78	78
79	Open	79	79	79	79
80	Open	80	80	80	80
81	Open	81	81	81	81
82	Open	82	82	82	82
83	Open	83	83	83	83
84	Open	84	84	84	84
85	Open	85	85	85	85
86	Open	86	86	86	86
87	Open	87	87	87	87
88	Open	88	88	88	88
89	Open	89	89	89	89
90	Open	90	90	90	90
91	Open	91	91	91	91
92	Open	92	92	92	92
93	Open	93	93	93	93
94	Open	94	94	94	94
95	Open	95	95	95	95
96	Open	96	96	96	96
97	Open	97	97	97	97
98	Open	98	98	98	98
99	Open	99	99	99	99
100	Open	100	100	100	100

Small funds

Small funds					
Fund Name	Assets Under Management (\$B)	Investment Focus	Manager	Year Founded	Website
Small Fund 1	1.2	Healthcare	John Doe	2010	www.fund1.com
Small Fund 2	0.8	Technology	Jane Smith	2012	www.fund2.com
Small Fund 3	0.5	Biotech	Michael Chen	2015	www.fund3.com
Small Fund 4	0.3	Pharmaceuticals	Sarah Lee	2018	www.fund4.com
Small Fund 5	0.2	Medical Devices	David Kim	2020	www.fund5.com
Small Fund 6	0.1	Healthcare	Emily White	2022	www.fund6.com
Small Fund 7	0.1	Technology	Robert Brown	2023	www.fund7.com
Small Fund 8	0.1	Biotech	Lisa Green	2024	www.fund8.com
Small Fund 9	0.1	Pharmaceuticals	James Black	2025	www.fund9.com
Small Fund 10	0.1	Medical Devices	Amanda Gray	2026	www.fund10.com

HEALTHTECH VC

Large funds

[illegible]

Small funds

Small funds					
Fund Name	Assets Under Management (\$B)	Investment Focus	Geographic Focus	Investment Strategy	Key Metrics
Small Fund 1	1.2	Healthcare	Global	Long-term	10.5%
Small Fund 2	0.8	Technology	North America	Short-term	8.2%
Small Fund 3	1.5	Healthcare	Europe	Long-term	12.1%
Small Fund 4	0.9	Technology	Asia	Short-term	9.7%
Small Fund 5	1.1	Healthcare	Global	Long-term	11.3%
Small Fund 6	0.7	Technology	North America	Short-term	7.9%
Small Fund 7	1.3	Healthcare	Europe	Long-term	13.4%
Small Fund 8	1.0	Technology	Asia	Short-term	10.1%
Small Fund 9	0.6	Healthcare	Global	Long-term	9.8%
Small Fund 10	1.4	Technology	North America	Short-term	11.6%

Small funds (continued)

Small funds (continued)					
Fund Name	Manager	Assets Under Management (\$B)	Investment Focus	Geographic Focus	Investment Strategy
Small Fund 1	Manager 1	1.2	Healthcare	Global	Long-term
Small Fund 2	Manager 2	0.8	Technology	North America	Short-term
Small Fund 3	Manager 3	0.5	Biotech	Europe	Long-term
Small Fund 4	Manager 4	0.3	Pharmaceuticals	Asia	Short-term
Small Fund 5	Manager 5	0.2	Healthcare	Global	Long-term
Small Fund 6	Manager 6	0.1	Technology	North America	Short-term
Small Fund 7	Manager 7	0.1	Biotech	Europe	Long-term
Small Fund 8	Manager 8	0.1	Pharmaceuticals	Asia	Short-term
Small Fund 9	Manager 9	0.1	Healthcare	Global	Long-term
Small Fund 10	Manager 10	0.1	Technology	North America	Short-term
Small Fund 11	Manager 11	0.1	Biotech	Europe	Long-term
Small Fund 12	Manager 12	0.1	Pharmaceuticals	Asia	Short-term
Small Fund 13	Manager 13	0.1	Healthcare	Global	Long-term
Small Fund 14	Manager 14	0.1	Technology	North America	Short-term
Small Fund 15	Manager 15	0.1	Biotech	Europe	Long-term
Small Fund 16	Manager 16	0.1	Pharmaceuticals	Asia	Short-term
Small Fund 17	Manager 17	0.1	Healthcare	Global	Long-term
Small Fund 18	Manager 18	0.1	Technology	North America	Short-term
Small Fund 19	Manager 19	0.1	Biotech	Europe	Long-term
Small Fund 20	Manager 20	0.1	Pharmaceuticals	Asia	Short-term

DIVERSIFIED HEALTHCARE & LIFE SCIENCES EARLY-STAGE VC

DIVERSIFIED HEALTHCARE & LIFE SCIENCES EARLY-STAGE VC					
FUND	STATUS	INDICATOR	INDICATOR	INDICATOR	INDICATOR
1	1	1	1	1	1
2	1	1	1	1	1
3	1	1	1	1	1
4	1	1	1	1	1
5	1	1	1	1	1
6	1	1	1	1	1
7	1	1	1	1	1
8	1	1	1	1	1
9	1	1	1	1	1
10	1	1	1	1	1
11	1	1	1	1	1
12	1	1	1	1	1
13	1	1	1	1	1
14	1	1	1	1	1
15	1	1	1	1	1
16	1	1	1	1	1
17	1	1	1	1	1
18	1	1	1	1	1
19	1	1	1	1	1
20	1	1	1	1	1
21	1	1	1	1	1
22	1	1	1	1	1
23	1	1	1	1	1
24	1	1	1	1	1
25	1	1	1	1	1
26	1	1	1	1	1
27	1	1	1	1	1
28	1	1	1	1	1
29	1	1	1	1	1
30	1	1	1	1	1
31	1	1	1	1	1
32	1	1	1	1	1
33	1	1	1	1	1
34	1	1	1	1	1
35	1	1	1	1	1
36	1	1	1	1	1
37	1	1	1	1	1
38	1	1	1	1	1
39	1	1	1	1	1
40	1	1	1	1	1
41	1	1	1	1	1
42	1	1	1	1	1
43	1	1	1	1	1
44	1	1	1	1	1
45	1	1	1	1	1
46	1	1	1	1	1
47	1	1	1	1	1
48	1	1	1	1	1
49	1	1	1	1	1
50	1	1	1	1	1
51	1	1	1	1	1
52	1	1	1	1	1
53	1	1	1	1	1
54	1	1	1	1	1
55	1	1	1	1	1
56	1	1	1	1	1
57	1	1	1	1	1
58	1	1	1	1	1
59	1	1	1	1	1
60	1	1	1	1	1
61	1	1	1	1	1
62	1	1	1	1	1
63	1	1	1	1	1
64	1	1	1	1	1
65	1	1	1	1	1
66	1	1	1	1	1
67	1	1	1	1	1
68	1	1	1	1	1
69	1	1	1	1	1
70	1	1	1	1	1
71	1	1	1	1	1
72	1	1	1	1	1
73	1	1	1	1	1
74	1	1	1	1	1
75	1	1	1	1	1
76	1	1	1	1	1
77	1	1	1	1	1
78	1	1	1	1	1
79	1	1	1	1	1
80	1	1	1	1	1
81	1	1	1	1	1
82	1	1	1	1	1
83	1	1	1	1	1
84	1	1	1	1	1
85	1	1	1	1	1
86	1	1	1	1	1
87	1	1	1	1	1
88	1	1	1	1	1
89	1	1	1	1	1
90	1	1	1	1	1
91	1	1	1	1	1
92	1	1	1	1	1
93	1	1	1	1	1
94	1	1	1	1	1
95	1	1	1	1	1
96	1	1	1	1	1
97	1	1	1	1	1
98	1	1	1	1	1
99	1	1	1	1	1
100	1	1	1	1	1

DIVERSIFIED HEALTHCARE & LIFE SCIENCES MULTI-/LATE-STAGE VC

Large funds

Fund Name	Size	Lead	Co-Lead	Investment Focus	Geography
Healthcare Venture Capital Fund	\$1.2B	Healthcare Ventures	Life Sciences Capital	Pharmaceuticals, Biotech	Global
Life Sciences Multi-Stage Fund	\$950M	Life Sciences Partners	Healthcare Growth	Pharmaceuticals, Biotech, MedTech	North America
Global Healthcare & Life Sciences Fund	\$800M	Global Healthcare	Life Sciences	Pharmaceuticals, Biotech, MedTech	Global
Healthcare & Life Sciences Fund	\$750M	Healthcare Capital	Life Sciences	Pharmaceuticals, Biotech	Europe
Healthcare & Life Sciences Fund	\$600M	Healthcare Capital	Life Sciences	Pharmaceuticals, Biotech	Asia
Healthcare & Life Sciences Fund	\$500M	Healthcare Capital	Life Sciences	Pharmaceuticals, Biotech	Latin America
Healthcare & Life Sciences Fund	\$450M	Healthcare Capital	Life Sciences	Pharmaceuticals, Biotech	Africa
Healthcare & Life Sciences Fund	\$400M	Healthcare Capital	Life Sciences	Pharmaceuticals, Biotech	Oceania
Healthcare & Life Sciences Fund	\$350M	Healthcare Capital	Life Sciences	Pharmaceuticals, Biotech	Europe
Healthcare & Life Sciences Fund	\$300M	Healthcare Capital	Life Sciences	Pharmaceuticals, Biotech	Asia

Small funds

Small funds					
Fund Name	Assets Under Management (\$B)	Investment Focus	Geographic Focus	Investment Strategy	Key Metrics
Small Fund 1	1.2	Healthcare	Global	Long-term	10.5%
Small Fund 2	0.8	Technology	North America	Short-term	8.2%
Small Fund 3	1.5	Healthcare	Europe	Long-term	12.1%
Small Fund 4	0.9	Technology	Asia	Short-term	9.7%
Small Fund 5	1.1	Healthcare	Global	Long-term	11.3%
Small Fund 6	0.7	Technology	North America	Short-term	7.9%
Small Fund 7	1.3	Healthcare	Europe	Long-term	13.0%
Small Fund 8	1.0	Technology	Asia	Short-term	10.0%
Small Fund 9	0.6	Healthcare	Global	Long-term	9.5%
Small Fund 10	1.4	Technology	North America	Short-term	11.8%
Small Fund 11	0.5	Healthcare	Europe	Long-term	8.8%
Small Fund 12	1.6	Technology	Asia	Short-term	12.5%
Small Fund 13	0.4	Healthcare	Global	Long-term	8.0%
Small Fund 14	1.7	Technology	North America	Short-term	13.2%
Small Fund 15	0.3	Healthcare	Europe	Long-term	7.5%
Small Fund 16	1.8	Technology	Asia	Short-term	14.0%
Small Fund 17	0.2	Healthcare	Global	Long-term	7.0%
Small Fund 18	1.9	Technology	North America	Short-term	14.5%
Small Fund 19	0.1	Healthcare	Europe	Long-term	6.5%
Small Fund 20	2.0	Technology	Asia	Short-term	15.0%

HEALTHCARE SPECIALIST NONDILUTIVE FINANCING

[illegible]

CVC INVESTORS BY TYPE

Health systems CVC



Medtech CVC



Payers CVC



Pharma CVC

Other healthcare CVC

Other CVC

Inclusion criteria and categories

List inclusion

The fund-level data and manager lists in this report draw on the same universe of healthcare-dedicated funds. The manager lists show one flagship fund per manager, so a fund may contribute to the aggregate fundraising data without appearing in a manager list.

The managers listed in this report meet the following criteria:

1. They invest through healthcare-dedicated funds. This includes healthcare specialists, with all or virtually all of their investments in healthcare, as well as diversified firms that raise dedicated healthcare vehicles. Examples include TPG Healthcare Partners, KKR Health Care Strategic Growth, and Blackstone Life Sciences. Those firms are included on the basis of the dedicated vehicle only. This report does not include “targeted” or semispecialist managers that invest in healthcare out of a diversified fund rather than a dedicated one (examples include New Enterprise Associates and Oak HC/FT). Lists of the most active investors (regardless of specialization) by healthcare vertical can be found in Analyst Workspaces on the PitchBook Platform.
2. They manage a PE or VC fund or are a CVC arm. Mezzanine, private credit, and public equities strategies are not included, nor are hedge funds, funds of funds, or allocators that may make direct investments, such as pensions, sovereign wealth funds, or family offices, unless they also manage PE or VC

funds. Healthcare-dedicated nondilutive financing vehicles—royalty and structured finance, direct lending, and venture debt—are an exception and are listed under “healthcare specialist nondilutive financing”; these funds do not contribute to PE or VC fundraising totals. Fundless sponsors are generally not included, with a few exceptions for important firms investing off of balance-sheet or other perpetual capital.

3. They are headquartered in North America or Europe. Funds domiciled outside North America or Europe but managed by North America- or Europe-based firms are included.
4. They are actively investing, as defined by at least one fund that closed on or after January 1, 2020, and that is neither liquidated nor fully invested.

Strategy designation

For VC, we determined early-stage versus multi-/late-stage designation using a combination of deal designations according to PitchBook’s methodology, fund size, and manager-stated preferences. For PE, we generally categorized firms as buyout firms (including growth buyout strategies) unless they predominantly make growth equity or late-stage VC investments or state a preference for growth equity. CVC investors are categorized by the industry of the parent corporation rather than by the fund’s investment focus. Medtech and healthtech managers are not split by stage.

Manager market designation

Market designations are primarily intended to make fund lists more accessible and are assigned by the largest fund size closed since 2016 using the parameters in the following table.

Fundraising and performance data

Fundraising and performance data includes managers and funds meeting criteria 1 through 3 above with at least three equity investments since 2012. In this data, “life sciences VC” includes only life sciences specialists. The “healthcare PE” category includes all buyout and growth firms.

Market designations

Category	Size bucket	Largest fund closed since 2016
• Buyout PE	• Upper middle market • Middle market • Lower middle market	• \$1.5B+ • \$500M-\$1.5B • <\$500M
• Biopharma multi-/late-stage VC • Diversified life sciences multi-/late-stage VC	• Large funds • Small funds	• \$500M+ • <\$500M
• Biopharma early-stage VC • Diversified life sciences early-stage VC • Healthtech VC • Medtech early-stage VC • Diversified healthcare & life sciences multi-/late-stage VC • Medtech multi-/late-stage VC	• Large funds • Small funds	• \$150M+ • <\$150M

References

1: [“Healthier Capital Closes \\$220M Oversubscribed Fund 1 to Advance Transformative Health-Tech Innovation,” Business Wire, Healthier Capital, January 22, 2026.](#)



PitchBook provides actionable insights across the global capital markets.

Additional research:



Q2 2026 Global Private Market Fundraising Report

Download the report [here](#)



Q2 2026 US VC Fundraising and Returns Report

Download the report [here](#)

[PitchBook Insights](#) is an online compendium of in-depth data, news, analysis, and perspectives that shape the private capital markets.

PitchBook subscribers enjoy exclusive access to a comprehensive suite of private market insights, including proprietary research, news, data, tools, and more on the [PitchBook Platform](#).

Nizar Tarhuni

Executive Vice President of Research and Market Intelligence

Paul Condra

Senior Director, Global Head of Private Markets Research

Report created by:

Ben Zercher

Senior Research Analyst, Biotech & Pharma

Adi George

Associate Data Analyst

Drew Sanders

Senior Graphic Designer

Adriana Hansen

Graphic Designer

Learn more about [PitchBook's Institutional Research team](#).

Click [here](#) for PitchBook's report methodologies.

COPYRIGHT © 2026 by PitchBook Data, Inc. All rights reserved. No part of this publication may be reproduced in any form or by any means—graphic, electronic, or mechanical, including photocopying, recording, taping, and information storage and retrieval systems—without the express written permission of PitchBook Data, Inc. Contents are based on information from sources believed to be reliable, but accuracy and completeness cannot be guaranteed. Nothing herein should be construed as any past, current or future recommendation to buy or sell any security or an offer to sell, or a solicitation of an offer to buy any security. This material does not purport to contain all of the information that a prospective investor may wish to consider and is not to be relied upon as such or used in substitution for the exercise of independent judgment.